1. Ada, G., 1991, Strategies for exploiting the immune system in the design of vaccines, Mol. Immunol. 28:225–230.
2. Ahlers, J. D., Pendleton, C. D., Dunlop, N., Minassian, A., Nara, P. L., and Berzofsky, J. A., 1993, Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations, J. Immunol. 150:5647–5665.
3. Aichele, P., Hengartner, H., Zinkernagel, R. M., and Schulz, M., 1990, Anti-viral cytotoxic T cell responses induced by in vivo priming with a free synthetic peptide, J. Exp. Med. 171:1815–1820.
4. Autran, B., Plata, F., and Debre, P., 1991, MHC-restricted cytotoxicity against HIV, J. AIDS 4:361–367.
5. Baba, E., Nakamura, M., Tanaka, Y., Kuroki, M., Itoyama, Y., Nakano, S., and Niho, Y., 1993, Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type I (HTLV-I) identified by human monoclonal antibodies, J. Immunol. 151:1013–1024.